SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Spero Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.12+0.02 (+1.82%)
Close on Oct 19, 2026
- Market cap
- $64.92M
- P/E (TTM)
- 28.0
- Dividend yield
- –
Spero Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Spero Therapeutics | Industry median |
|---|---|---|
| Market Cap | $65.22M | $166.30M |
| Enterprise Value | $14.45M | $88.19M |
| PE Ratio | 28.00 | 20.44 |
| PS Ratio | 1.39 | 3.65 |
| PB Ratio | 1.48 | 2.03 |
| P/TBV Ratio | 1.48 | 2.29 |
| P/OCF Ratio | 3.33 | 12.98 |
Enterprise value
| Measure | Spero Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 0.31 | 2.51 |
| EV / EBITDA | 2.40 | 14.65 |
| EV / EBIT | 2.40 | 19.00 |
Income (trailing twelve months)
| Measure | Spero Therapeutics | Industry median |
|---|---|---|
| Revenue | $47.00M | $58.34M |
| Operating Income | $6.03M | -$21.40M |
| Net Income | $7.38M | -$22.46M |
| EBITDA | $6.03M | -$16.91M |
| EPS (Diluted) | $0.04 | -$0.83 |
Margins
| Measure | Spero Therapeutics | Industry median |
|---|---|---|
| Operating Margin | 12.8% | -44.0% |
| Profit Margin | 15.7% | -40.2% |
| EBITDA Margin | 12.8% | -30.2% |
Returns
| Measure | Spero Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | 19.2% | -53.2% |
| Return on Assets (ROA) | 12.9% | -40.9% |
| Return on Capital Employed (ROCE) | 13.6% | -38.1% |
Growth
| Measure | Spero Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -3.25% | 5.96% |
| Revenue Growth (3Y CAGR) | 7.68% | 2.25% |
| Revenue Growth (5Y CAGR) | 48.2% | 6.48% |
Balance sheet
| Measure | Spero Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $50.77M | $61.43M |
| Net Cash (Debt) | $50.77M | $15.35M |
| Net Cash Per Share | $0.87 | $0.66 |
| Equity (Book Value) | $44.20M | $49.09M |
| Book Value Per Share | $0.76 | $1.37 |
| Tangible Book Value | $44.20M | $23.52M |
| Working Capital | $43.16M | $76.81M |
Financial position
| Measure | Spero Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 6.12 | 3.34 |
| Quick Ratio | 6.02 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Spero Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | $19.58M | -$12.35M |
Efficiency
| Measure | Spero Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.82 | 0.39 |
| Revenue Per Employee | $1.88M | $404.87K |
| Profits Per Employee | $295.32K | -$703.34K |
| Employee Count | 25 | 74 |
Dividends and yields
| Measure | Spero Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | 11.3% | -23.3% |
Shares
| Measure | Spero Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 58,234,800 | 58,127,000 |
| Shares Change (YoY) | 9.10% | 10.9% |
| Shares Change (QoQ) | 0.44% | 0.54% |
| Float | 43,885,900 | 49,136,700 |
| Shares Held by Insiders | 24.6% | 11.6% |
| Shares Held by Institutions | 36.9% | 59.4% |
Scores
| Measure | Spero Therapeutics | Industry median |
|---|---|---|
| Graham Number | $0.83 | $18.73 |
| Graham Upside | -26.2% | -45.1% |
| Altman Z-Score | -5.59 | -0.22 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from Spero Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.